CO124 Indirect Comparison of Efficacy and Safety for Aumolertinib vs Osimertinib in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Autor: S Stergiopoulos, S King, M Curtis, SA Dillon, R Akehurst, D Lee, F Guelfucci, A Ngami, F Bianic, Y Li, X Ma, S Ali, VA Miller, S Popat

Publikováno v: Value in Health. 25:S42

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7343225005b68e775443f76c55ff001e
https://doi.org/10.1016/j.jval.2022.09.202

Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings

Autor: JS Ross, J Chung, JE Elvin, J-A Vergilio, S Ramkissoon, J Suh, E Severson, S Daniel, GM Frampton, D Fabrizio, RJ Hartmaier, LA Albacker, SM Ali, AB Schrock, VA Miller, PJ Stephens, LM Gay

Publikováno v: Cancer Research. 78:P2-09

Background: The tropomysin receptor kinase A family includes the 3 NTRK1, NTRK2 and NTRK3 genes and plays major roles in neuronal development. The recent evidence of remarkable efficacy for kinase inhibitors (TKI) targeting NTRK across a wide variety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b4b8073a0a60f01beaf32cf13a2c573e
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-15

Abstract P1-05-07: Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation

Autor: LM Gay, JA Elvin, J-A Vergilio, J Suh, S Ramkissoon, S Ali, A Schrock, K Hirshfield, S Ganesan, VA Miller, PJ Stephens, JS Ross

Publikováno v: Cancer Research. 77:P1-05

Background: Malignant or metastatic breast phyllodes tumors (MPT) are exceptionally rare, and the underlying genomic drivers are still being elucidated. Recent studies report frequent mutations in the RAS and PI3K pathways but have not commonly repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e3861e73d01f05ebfbb2ef28b1638e7
https://doi.org/10.1158/1538-7445.sabcs16-p1-05-07

Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies

Autor: JS Ross, J Chung, JE Elvin, J-A Vergilio, S Ramkissoon, J Suh, E Severson, S Daniel, GM Frampton, D Fabrizio, RJ Hartmaier, LA Albacker, SM Ali, AB Schrock, VA Miller, PJ Stephens, LM Gay

Publikováno v: Cancer Research. 78:PD8-01

Background: Typically defined by negative IHC staining for E-cadherin, classic (CILC) and pleomorphic (PILC) are often combined as a single breast cancer subtype. We queried whether patients with relapsed metastatic disease, mCILC and mPILC, would ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02b3a044b20641eb707ff270a21ebb7f
https://doi.org/10.1158/1538-7445.sabcs17-pd8-01

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.

Autor: Turner JA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Van Gulick RJ; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Robinson WA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Mughal T; Division of Hematology-Oncology, Tufts University Cancer Center, Boston, Massachusetts, USA., Tobin RP; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., MacBeth ML; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Holman B; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Classon A; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Bagby SM; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Yacob BW; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Hartman SJ; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Silverman I; Ignyta, Inc., San Diego, California, USA., Vorwald VM; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gorden N; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gonzalez R; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gay LM; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Ali SM; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Benson A; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Miller VA; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts, USA.; Department of Pathology, Upstate Medical University, Syracuse, New York, USA., Pitts TM; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Rioth MJ; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Lewis KD; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Medina T; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., McCarter MD; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gonzalez R; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Couts KL; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Jul 12. Date of Electronic Publication: 2024 Jul 12.